-
-
-
-
-
-
-
FDA approves Pfizer's Ibrance for HR+, HER2+ metastatic breast cancer
-
-
-
-
-
-
-
FreeCast surges premarket; Accenture, Novocure slide
-
-
-
-
-
-
-
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
-
-
-
-
-
-
-
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
-
-
-
-
-
-
-
Raymond James on BridgeBio Pharma (BBIO): 'We expect continued strong commercial momentum for Attruby'
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Pfizer (PFE)
-
1,208,466 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

